January 31, 2023 — Pfizer Inc. (NYSE:PFE) reported exceptional financial results for fourth-quarter and full-year 2022 and provided 2023 financial guidance.
Pfizer Inc. (NYSE:PFE) reported Q4 adjusted earnings of $1.14 per diluted share, up from $0.79 a year earlier.
Analysts polled by Capital IQ expected $1.04.
Revenue for the quarter was $24.29 billion, up from $23.84 billion a year earlier. Analysts surveyed by Capital IQ expected $24.40 billion.
The company said it is expecting fiscal 2023 adjusted earnings of $3.25 to $3.45 per diluted share. Analysts polled by Capital IQ are expecting $4.38.
Revenue for the year is expected to range between $67 billion and $71 billion. Analysts surveyed by Capital IQ are expecting $74.23 billion.
Fourth-Quarter 2022 Revenues of $24.3 Billion, Reflecting 13% Operational Growth，Excluding Contributions from Paxlovid and Comirnaty(1), Revenues Grew 5% Operationally。
Full-Year 2022 Revenues of $100.3 Billion, An All-Time High for Pfizer, Reflecting 30% Operational Growth，Excluding Contributions from Paxlovid and Comirnaty, Revenues Grew 2% Operationally。
Full-Year 2022 Reported Diluted EPS of $5.47, Up 42% Year-Over-Year, and Adjusted Diluted EPS of $6.58, Up 62% Year-Over-Year, Both of Which Represent All-Time Highs for Pfizer。
full-year 2023 Guidance
Revenue of $67.0 to $71.0 Billion
Adjusted Diluted EPS of $3.25 to $3.45
Return on capital
During full-year 2022, Returning capital directly to shareholders through a combination of:
$9.0 billion of cash dividends, or $1.60 per share of common stock, and $2.0 billion, which was used to repurchase 39.1 million shares on the open market in March 2022, at an average cost of $51.10 per share.
As of January 31, 2023, Pfizer’s remaining share repurchase authorization is $3.3 billion. Current financial guidance does not anticipate any share repurchases in 2023.